| Bioactivity | Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV[1][2][3]. | ||||||||||||
| Invitro | Tenatoprazole (TU-199) (0.1, 0.2, 0.4 mg/kg; oral; single; Heidenhain-pouch dogs) dose-dependently suppresses gastric acid secretion stimulated by histamine infusion[4]. | ||||||||||||
| Name | Tenatoprazole | ||||||||||||
| CAS | 113712-98-4 | ||||||||||||
| Formula | C16H18N4O3S | ||||||||||||
| Molar Mass | 346.40 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Thomson AB, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23(8):1179-1187 [2]. Uchiyama K, et al. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999;21(2):115-122. [3]. Mannemuddhu SS, et al. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency. J Virol. 2021;95(13):e0246620. [4]. Uchiyama K, et al. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999;51(4):457-464. |
Tenatoprazole
CAS: 113712-98-4 F: C16H18N4O3S W: 346.40
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.